WASHINGTON: Merck's anti-Covid pill remains "active" against the Omicron variant, the US drugmaker said Friday (Jan 28), citing results from six laboratory studies.
The oral treatment, called molnupiravir, is taken within five days of symptom onset and was shown in a pre-Omicron trial of 1,400 participants to reduce Covid hospitalisations and deaths by 30 percent among at-risk people.
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!
